These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 28438583)

  • 1. Psychometric Assessment of the Chinese Version of the Abbreviated Expanded Prostate Cancer Index Composite (EPIC-26) and the Clinical Practice Version (EPIC-CP) in Chinese Men With Prostate Cancer.
    Lam WWT; Tse MA; Ng CNL; Chung EKM; Fielding R
    J Pain Symptom Manage; 2017 Jun; 53(6):1085-1090. PubMed ID: 28438583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of the Italian version of the abbreviated expanded prostate Cancer index composite (EPIC-26) in men with prostate Cancer.
    Marzorati C; Monzani D; Mazzocco K; Masiero M; Pavan F; Monturano M; Pravettoni G
    Health Qual Life Outcomes; 2019 Aug; 17(1):147. PubMed ID: 31464649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychometric testing of the Norwegian version of the Expanded Prostate Cancer Index Composite 26-item version (EPIC-26).
    Fosså SD; Storås AH; Steinsvik EA; Myklebust TA; Eri LM; Loge JH; Dahl AA
    Scand J Urol; 2016 Aug; 50(4):280-5. PubMed ID: 27049891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Portuguese version of the Expanded Prostate Cancer Index Composite for Clinical Practice (EPIC-CP): psychometric validation and prospective application for early functional outcomes at a single institution.
    Lourenço DB; Amaral BS; Alfer-Junior W; Vasconcellos A; Russo F; Sanchez-Salas R; Bianco B; Wagner AA; Chang P; Moschovas MC; Lemos GC; Carneiro A
    BMC Urol; 2020 Oct; 20(1):163. PubMed ID: 33081748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-cultural adaptation and validation of the French version of the Expanded Prostate cancer Index Composite questionnaire for health-related quality of life in prostate cancer patients.
    Anota A; Mariet AS; Maingon P; Joly F; Bosset JF; Guizard AV; Bittard H; Velten M; Mercier M
    Health Qual Life Outcomes; 2016 Dec; 14(1):168. PubMed ID: 27923377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychometric properties of the expanded prostate cancer index composite - 26 instrument in a cohort of radical prostatectomy patients: theoretical and practical examinations.
    Axcrona K; Nilsson R; Brennhovd B; Sørebø Ø; Fosså SD; Dahl AA
    BMC Urol; 2017 Dec; 17(1):111. PubMed ID: 29197360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer.
    Wei JT; Dunn RL; Litwin MS; Sandler HM; Sanda MG
    Urology; 2000 Dec; 56(6):899-905. PubMed ID: 11113727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-related quality of life in men with localized prostate cancer treated with radiotherapy: validation of an abbreviated version of the Expanded Prostate Cancer Index Composite for Clinical Practice in Spain.
    Zapatero A; Maldonado Pijoan X; Gómez-Caamaño A; Pardo Masferrer J; Macías Hernández V; Hervás Morón A; Muñoz García JL; Palacios Eito A; Anguita-Alonso P; González-Junco C; López Torrecilla J
    Health Qual Life Outcomes; 2021 Sep; 19(1):223. PubMed ID: 34563208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Quality of life in patients with prostate cancer: validation of an instrument for clinical practice].
    Balbontín F; Marchetti P; Moreno S; Cabello JM; Urzúa C; Silva A; Avilés J; Badínez L; García J; Salgado A; Vinez E; Alliende I; Canals A; Velasco A
    Arch Esp Urol; 2015 Jun; 68(5):466-73. PubMed ID: 26102050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Use of Expanded Prostate Cancer Index Composite for Clinical Practice to Assess Patient Reported Prostate Cancer Quality of Life Following Robot-Assisted Radical Prostatectomy.
    Wagner AA; Cheng PJ; Carneiro A; Dovirak O; Khosla A; Taylor KN; Crociani CM; McAnally KC; Percy A; Dewey LE; Sanda MG; Chang P
    J Urol; 2017 Jan; 197(1):109-114. PubMed ID: 27475967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors.
    Szymanski KM; Wei JT; Dunn RL; Sanda MG
    Urology; 2010 Nov; 76(5):1245-50. PubMed ID: 20350762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of the French-Canadian version of the Expanded Prostate Cancer Index Composite (EPIC) in a French-Canadian population.
    Vigneault É; Savard J; Savard MH; Ivers H; Després P; Foster W; Martin AG; Fradet V
    Can Urol Assoc J; 2017 Dec; 11(12):404-410. PubMed ID: 29106365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot evaluation of the expanded prostate cancer index composite for clinical practice (EPIC-CP) tool in Ontario.
    Brundage MD; Barbera L; McCallum F; Howell DM
    Qual Life Res; 2019 Mar; 28(3):771-782. PubMed ID: 30382479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The German version of the Expanded Prostate Cancer Index Composite (EPIC): translation, validation and minimal important difference estimation.
    Umbehr MH; Bachmann LM; Poyet C; Hammerer P; Steurer J; Puhan MA; Frei A
    Health Qual Life Outcomes; 2018 Feb; 16(1):36. PubMed ID: 29458434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expanded Prostate Cancer Index Composite-26 (EPIC-26) Online: Validation of an Internet-Based Instrument for Assessment of Health-Related Quality of Life After Treatment for Localized Prostate Cancer.
    Einstein DJ; Patil D; Chipman J; Regan MM; Davis K; Crociani CM; Wagner AA; Sanda MG; Chang P
    Urology; 2019 May; 127():53-60. PubMed ID: 30790648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Psychometric validation of the Spanish version of the Expanded Prostate Cancer Index Composite-26.
    Zamora V; Garin O; Suárez JF; Jové J; Castells M; Ferrer F; Gutiérrez C; Guedea F; Boladeras A; Fumadó L; Roselló A; Pastor J; Samper P; Pont À; Ferrer M
    World J Urol; 2023 Dec; 41(12):3511-3518. PubMed ID: 37947846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychometric validation of the German version of the EPIC-26 questionnaire for patients with localized and locally advanced prostate cancer.
    Sibert NT; Dieng S; Oesterle A; Feick G; Carl G; Steiner T; Minner J; Roghmann F; Kaftan B; Zengerling F; Hinkel A; Beyer B; Heidenreich A; Harke N; Brehmer B; Pfitzenmaier J; Fichtner J; Neisius A; Hammerer P; Wesselmann S; Kowalski C
    World J Urol; 2021 Jan; 39(1):11-25. PubMed ID: 31552467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure.
    Litwin MS; Hays RD; Fink A; Ganz PA; Leake B; Brook RH
    Med Care; 1998 Jul; 36(7):1002-12. PubMed ID: 9674618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Creation and Psychometric Validation of the Sexual Minorities and Prostate Cancer Scale (SMACS) in Sexual Minority Patients-The Restore-2 Study.
    Polter EJ; Kohli N; Rosser BRS; Talley KMC; Wheldon CW; Hoefer CJ; Wright M; Haggart R; Mitteldorf D; Kilian G; Konety BR; Ross MW; West W
    J Sex Med; 2022 Mar; 19(3):529-540. PubMed ID: 35131199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cultural adaptation and validation of the Chinese version of the expanded prostate cancer index composite.
    Lee TK; Poon DMC; Ng ACF; Ho T; Singh-Carlson S; Joffres M; Oshan G; Kohli J; Kwan W
    Asia Pac J Clin Oncol; 2018 Mar; 14 Suppl 1():10-15. PubMed ID: 29508938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.